![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics to Webcast Presentation at 26th Annual Piper Jaffray Healthcare Conference
25 nov. 2014 16h01 HE
|
Cara Therapeutics
SHELTON, Conn., Nov. 25, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics to Webcast Presentation at 2014 Stifel Healthcare Conference
11 nov. 2014 16h01 HE
|
Cara Therapeutics
SHELTON, Conn., Nov. 11, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics Reports Third Quarter 2014 Financial Results
10 nov. 2014 16h01 HE
|
Cara Therapeutics
Reported positive top-line data from human abuse liability trial for I.V. CR845
Phase 3 registration trials for I.V. CR845 expected to initiate in early 2015
Conference call today at...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics to Announce Third Quarter 2014 Financial Results on November 10, 2014
03 nov. 2014 16h01 HE
|
Cara Therapeutics
SHELTON, Conn., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics Announces Positive Results From Human Abuse Liability Trial of Peripheral Opioid for Acute Pain, I.V. CR845
29 oct. 2014 07h00 HE
|
Cara Therapeutics
Trial meets primary endpoint with I.V. CR845 showing highly statistically significant reductions (p <0.0001) in scores for "drug liking," as well as "feeling high", "overall liking", and "take...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics Announces the Unexpected Death of Chief Medical Officer Dr. Robert Medve
27 oct. 2014 08h45 HE
|
Cara Therapeutics
SHELTON, Conn., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics to Sponsor Symposium at American Academy of Pain Management 2014 Annual Clinical Meeting
17 sept. 2014 08h00 HE
|
Cara Therapeutics
SHELTON, Conn., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics Reports Second Quarter 2014 Financial Results
07 août 2014 16h01 HE
|
Cara Therapeutics
SHELTON, Conn., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics Initiates Proof-of-Concept Phase II Trial of I.V. CR845 in Uremic Pruritus
06 août 2014 08h00 HE
|
Cara Therapeutics
Two-part study to evaluate safety, pharmacokinetics and anti-itch effects in hemodialysis patients
Top-line data expected in first half of 2015
SHELTON, Conn., Aug. 6, 2014 (GLOBE...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics to Announce Second Quarter 2014 Financial Results on August 7, 2014
31 juil. 2014 16h01 HE
|
Cara Therapeutics
SHELTON, Conn., July 31, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...